Assessing the critical success factors for implementing industry 4.0 in the pharmaceutical industry: Implications for supply chain sustainability in emerging economies

Abstract

The emerging technologies of Industry 4.0 (I4.0) are crucial to incorporating agility, sustainability, smartness, and competitiveness in the business model, enabling long-term sustainability practices in the pharmaceutical supply chain (PSC). By leveraging the latest technologies of I4.0, pharmaceutical companies can gain real-time visibility into their supply chain (SC) operations, allowing them to make data-driven decisions that improve SC performance, efficiency, resilience, and sustainability. However, to date, no research has examined the critical success factors (CSFs) that enable the pharmaceutical industry to adopt I4.0 successfully to enhance overall SC sustainability. This study, therefore, analyzed the potential CSFs for adopting I4.0 to increase all facets of sustainability in the PSC, especially from the perspective of an emerging economy like Bangladesh. Initially, sixteen CSFs were identified through a comprehensive literature review and expert validation. Later, the finalized CSFs were clustered into three relevant groups and analyzed using a Bayesian best-worst method (BWM)-based multi-criteria decision-making (MCDM) framework. The study findings revealed that "sufficient investment for technological advancement", "digitalized product monitoring and traceability", and "dedicated and robust research and development (R&D) team" are the top three CSFs to adopt I4.0 in the PSC. The study’s findings can aid industrial practitioners, managers, and policymakers in creating effective action plans for efficiently adopting I4.0 in PSC to avail of its competitive benefits and ensure a sustainable future for the pharmaceutical industry.

Analysis of the fire risks and mitigation approaches in the apparel manufacturing industry: Implications toward operational safety and sustainability

“…A panel of 19 industrial fire experts was selected purposively for this study. Purposive or judgemental selection of decision-makers is necessary where specialized opinion can only serve the study objectives, which a random sample of decision-makers cannot do [ 36 , 66 ]. Unlike other casual sampling methods, purposive sampling depends on an expert evaluation of the sample's appropriateness and a compelling justification that a specified sample of participants gives a credible base for survey-experimental results [ 67 ].…”

Exploring the Challenges of Industry 4.0 Adoption in the FMCG Sector: Implications for Resilient Supply Chain in Emerging Economy

“…The survey work was divided into two phases in this study. Firstly, using the snowballing technique, the challenges that impede the adoption of I4.0 to facilitate a resilient supply chain in the FMCG industry were discovered from the existing literature [55]. With a timeline of 2021-2023, the factors were searched in the Google Scholar and Scopus databases.…”

“…However, 12 experts (67.67%) consented to participate in the survey (factor validation and factor analysis). Twelve (12) industry leaders in each field were questioned to identify and aggregate the key elements for further inquiry [55]. The overall profile of the 12 responding experts is shown in Table 4.…”

Technology adoption theories towards environmentally sustainable pharma 4.0: a rational selection approach

“…Sustainable Pharma 4.0 encompasses the integration of Industry 4.0 technologies into the pharmaceutical sector while maintaining a strong focus on environmental sustainability. This approach aims to optimize various aspects of pharmaceutical operations, including manufacturing processes, supply chain management and drug development, through the adoption of advanced technologies such as AI, Internet of Things (IoT), big data analytics and automation(Debnath et al, 2023). By leveraging these technologies, pharmaceutical companies can achieve greater operational efficiency, minimize waste generation and reduce their overall environmental impact.…”